Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.650
+0.050 (3.13%)
At close: Dec 20, 2024, 4:00 PM
1.660
+0.010 (0.61%)
After-hours: Dec 20, 2024, 6:26 PM EST
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.
It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome.
Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Longeveron Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Mohamed Wa'el Hashad |
Contact Details
Address: Life Science & Technology Park, Suite 520 Miami, Florida 33136 United States | |
| Phone | 844 470 2550 |
| Website | longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L1044 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mohamed Wa'el Ahmed Hashad M.B.A. | Chief Executive Officer and Director |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer and Chairman |
| Lisa A. Locklear M.B.A. | Chief Financial Officer and Treasurer |
| Paul T. Lehr J.D. | International Executive Director, General Counsel and Secretary |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations and Scientific Affairs |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Brian G Rash Ph.D. | Vice President of Research and Discovery |
| Elly Ryu | Vice President and Corporate Controller |
| Michael Mannarino | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 27, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |
| Aug 12, 2024 | 424B3 | Prospectus |
| Aug 8, 2024 | UPLOAD | Filing |
| Aug 6, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |